Itulazax

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual formulation for sublingual use. It is employed in allergy immunotherapy to desensitize individuals with sensitivity to birch pollen and related allergens. The preparation is administered under medical supervision and is intended to modify the immune response, reducing symptoms such as nasal congestion, sneezing, and ocular irritation associated with birch pollen exposure. Treatment is typically part of a broader allergen immunotherapy program that may include other relevant extracts.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Itulazax, a sublingual allergen extract, is used in allergy immunotherapy targeting birch pollen–related hypersensitivity. - Birch pollen allergic rhinitis: reduces nasal congestion, sneezing, and itching by inducing tolerance to birch pollen. - Birch pollen‑induced allergic conjunctivitis: alleviates eye redness, tearing, and itching through immune modulation. - Oral allergy syndrome related to birch: diminishes oral itching and swelling when consuming cross‑reactive foods.

Common Side Effects: - Oral itching or mild throat irritation. - Transient nasal congestion or sneezing. - Mild gastrointestinal discomfort such as nausea. - Headache or mild fatigue. - Localized swelling of the lips or tongue. - Temporary increase in allergic symptoms after the first dose.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Angioedema affecting the face, lips, or airway. - Severe urticaria or widespread hives. - Respiratory distress requiring emergency intervention. - Cardiovascular collapse or hypotension.

Before initiating therapy, patients should be evaluated for suitability and monitored closely. - Medical supervision: administration must occur under physician guidance. - Allergy testing: confirm birch pollen sensitivity prior to use. - Pregnancy and lactation: discuss potential risks with a healthcare provider. - Concomitant medications: avoid beta‑blockers that may mask anaphylaxis. - Adverse reaction monitoring: observe the patient for at least 30 minutes after the first dose. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed before treatment. Major Interactions (Avoid): - Beta‑blockers: may interfere with emergency treatment of anaphylaxis. - ACE inhibitors: increase the risk of angioedema. Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of a systemic reaction. - Immunosuppressants: could reduce the efficacy of immunotherapy. - Other allergen extracts: concurrent use may raise the likelihood of systemic allergic responses.